G. Gademann

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

R. Jakesz, W. Jonat, Michael Gnant et al. · The Lancet · 2005 · 876 citations

Medicine, Endocrinology, Oncology +15

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

Ursula Nestle, Tanja Schimek‐Jasch, Stephanie Kremp et al. · The Lancet Oncology · 2020 · 177 citations

Medicine, Oncology, Radiation Oncology +14

The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.

Serban Dan Costa, G von Minckwitz, Günther Raab et al. · PubMed · 1999 · 37 citations

Medicine, Oncology, Pharmacology +13

Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study

M. Kaufmann, W. Jonat, J. Hilfrich et al. · Journal of Clinical Oncology · 2006 · 35 citations

Pharmacy, Oncology, Pharmacotherapy +17

[The value of radiotherapy for liver metastases].

Eble Mj, G. Gademann, M. Wannenmacher · PubMed · 1993 · 13 citations

Medicine, Oncology, Radiation Oncology +12